---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-091744"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2022-08-16T23:59:59+00:00"
generated_at: "2026-06-23T23:25:08.408205+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences elects Katherine Bach Kalin to its Board of Directors

## Summary
- Elected on Aug 13, 2022 as Class II director, term until 2024 annual meeting.
- Granted option for 19,000 shares at $3.10/share, vesting one year from grant.
- Over 25 years life sciences experience; led corporate strategy at Celgene 2012-2017.
- Also on boards of Genfit (GNFT), Brown Advisory, and FemHealth Ventures.
- Board determined she is independent under SEC and Nasdaq rules.

## SEC filing metadata
- accession: 0001104659-22-091744
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2022-08-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465922091744/0001104659-22-091744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465922091744/tm2223534d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-091744
- JSON: https://secwatch.observer/filing/0001104659-22-091744.json
- Plain text: https://secwatch.observer/filing/0001104659-22-091744.txt

## Key facts
- Executive change
  Katherine Bach Kalin was elected as Director at SELLAS Life Sciences Group, Inc..
  - Action: elected
  - Role: Director
  source text: On August 13, 2022, the Board of Directors (the “Board”) of SELLAS Life Sciences Group, Inc. (the “Company”) elected Katherine Bach Kalin as a member of the Board, effective immediately, to serve as a Class II director until the Company’s 2024 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465922091744/0001104659-22-091744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.